Literature DB >> 6682293

Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy.

D M Robertson, D Ilstrup.   

Abstract

The role of argon laser photocoagulation in the management of central serous choriorectinopathy was evaluated in a prospective randomized study of eyes with leaks smaller than 250 microns in diameter in the early frames of the angiogram. Eyes were assigned to Group A when the leak was located in the papillomacular bundle or within 500 microns of the capillary-free zone and to Group B when the leakage site was located outside the papillomacular bundle and more than 500 microns from the capillary-free zone. Thirty eyes in Group A underwent either a sham argon laser treatment or a real argon laser treatment directed to the pigment epithelium under the elevated retina at a site remote from the site of fluorescein dye leakage (indirect laser photocoagulation). Twelve eyes in Group B underwent either a laser treatment directed to the site of fluorescein dye leakage (direct laser photocoagulation) or indirect laser photocoagulation. Compared with indirect photocoagulation, direct laser photocoagulation shortened the duration of central serous chorioretinopathy by approximately two months, a statistically significant difference. When compared to sham treatment, indirect photocoagulation did not significantly alter the duration of central serous chorioretinopathy. During an 18-month interval, the recurrence rate in the eyes treated with sham and indirect laser photocoagulation was 34%, whereas no recurrences were observed in the eyes treated with direct photocoagulation. There were no complications from photocoagulation in any of the eyes.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6682293     DOI: 10.1016/0002-9394(83)90265-9

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  58 in total

1.  [Central serous chorioretinopathy (CSC)].

Authors:  H Baraki; N Feltgen; J Roider; H Hoerauf; C Klatt
Journal:  Ophthalmologe       Date:  2010-05       Impact factor: 1.059

2.  Subthreshold diode laser micropulse photocoagulation versus intravitreal injections of bevacizumab in the treatment of central serous chorioretinopathy.

Authors:  M J Koss; I Beger; F H Koch
Journal:  Eye (Lond)       Date:  2011-11-11       Impact factor: 3.775

3.  Effects of photodynamic therapy with verteporfin for the treatment of chronic central serous chorioretinopathy: An uncontrolled, open-label, observational study.

Authors:  Yildirim Bayezit Sakalar; Ugur Keklikci; Kaan Unlu; Mehmet Fuat Alakus; Ismail Hamdi Kara
Journal:  Curr Ther Res Clin Exp       Date:  2010-06

4.  Selective retina therapy in patients with central serous chorioretinopathy.

Authors:  H Elsner; E Pörksen; C Klatt; A Bunse; D Theisen-Kunde; R Brinkmann; R Birngruber; H Laqua; J Roider
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-12       Impact factor: 3.117

5.  Half-dose vs one-third-dose photodynamic therapy for chronic central serous chorioretinopathy.

Authors:  R Uetani; Y Ito; K Oiwa; K Ishikawa; H Terasaki
Journal:  Eye (Lond)       Date:  2012-05       Impact factor: 3.775

6.  Central serous chorioretinopathy: to treat or not to treat?

Authors:  J J De Laey
Journal:  Doc Ophthalmol       Date:  1986-01-15       Impact factor: 2.379

7.  Detection of local tissue alteration during retinal laser photocoagulation of ex vivo porcine eyes using phase-resolved optical coherence tomography.

Authors:  Shuichi Makita; Yoshiaki Yasuno
Journal:  Biomed Opt Express       Date:  2017-05-24       Impact factor: 3.732

8.  Long-term follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy.

Authors:  L Ficker; G Vafidis; A While; P Leaver
Journal:  Br J Ophthalmol       Date:  1988-11       Impact factor: 4.638

9.  Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy.

Authors:  Francesco Pichi; Paola Carrai; Antonio Ciardella; Francine Behar-Cohen; Paolo Nucci
Journal:  Int Ophthalmol       Date:  2016-10-18       Impact factor: 2.031

10.  One-year results of reduced fluence photodynamic therapy for central serous chorioretinopathy: the outer nuclear layer thickness is associated with visual prognosis.

Authors:  Yasuhiro Ohkuma; Takaaki Hayashi; Tsutomu Sakai; Akira Watanabe; Hiroshi Tsuneoka
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-03-02       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.